COSELA (trilaciclib hydrochloride for injection), the world’s first myeloprotective drug for pre-chemotherapy use.

KylinRay-TPSe, China’s first domestically developed precision radiotherapy device for cancer treatment.

As one of Nanjing’s key innovative industrial clusters, the city is home to over 1,000 high-tech biopharmaceutical enterprises, contributing to an industry revenue exceeding 200 billion RMB.

Recently, Nanjing-based IASO Bio made headlines with its first domestically developed CAR-T therapy, successfully entering the Hong Kong market. Meanwhile, GeneMind has established its East China R&D center in Nanjing, further solidifying the city’s position as a biotech hub.

With 4 specialized biopharmaceutical institutions and 20+ top universities offering related programs, Nanjing boasts one of the largest talent pools in China, producing over 60,000 biopharmaceutical graduates annually.

Nanjing is proving to the world that Chinese innovation is delivering solutions to global healthcare challenges.